Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285992816> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W4285992816 endingPage "274" @default.
- W4285992816 startingPage "273" @default.
- W4285992816 abstract "Treatment for triple-negative breast cancers has always been perceived as a “north face” (an allusion to the fact that the north face of a mountain in the northern hemisphere is usually the most formidable and challenging for mountain climbers), and numerous studies have failed to confirm that particular treatments confer a substantial benefit. In this issue of the Journal, Cortes et al.1 report that pembrolizumab — a breakthrough therapeutic treatment for patients with advanced triple-negative breast cancer — combined with chemotherapy prolonged overall survival among these patients. These results confirm the relationship between programmed death ligand 1 (PD-L1) expression and . . ." @default.
- W4285992816 created "2022-07-21" @default.
- W4285992816 creator A5044903892 @default.
- W4285992816 date "2022-07-21" @default.
- W4285992816 modified "2023-10-17" @default.
- W4285992816 title "Pembrolizumab in the Treatment of Breast Cancer" @default.
- W4285992816 cites W2133573244 @default.
- W4285992816 cites W2344657883 @default.
- W4285992816 cites W2785217251 @default.
- W4285992816 cites W2902530914 @default.
- W4285992816 cites W2948720210 @default.
- W4285992816 cites W2948726637 @default.
- W4285992816 cites W3109853980 @default.
- W4285992816 cites W3135755572 @default.
- W4285992816 cites W4229079181 @default.
- W4285992816 cites W4285992810 @default.
- W4285992816 doi "https://doi.org/10.1056/nejme2207532" @default.
- W4285992816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35857664" @default.
- W4285992816 hasPublicationYear "2022" @default.
- W4285992816 type Work @default.
- W4285992816 citedByCount "0" @default.
- W4285992816 crossrefType "journal-article" @default.
- W4285992816 hasAuthorship W4285992816A5044903892 @default.
- W4285992816 hasConcept C121608353 @default.
- W4285992816 hasConcept C126322002 @default.
- W4285992816 hasConcept C143998085 @default.
- W4285992816 hasConcept C2776694085 @default.
- W4285992816 hasConcept C2777701055 @default.
- W4285992816 hasConcept C2780057760 @default.
- W4285992816 hasConcept C2780110267 @default.
- W4285992816 hasConcept C2992734768 @default.
- W4285992816 hasConcept C530470458 @default.
- W4285992816 hasConcept C71924100 @default.
- W4285992816 hasConceptScore W4285992816C121608353 @default.
- W4285992816 hasConceptScore W4285992816C126322002 @default.
- W4285992816 hasConceptScore W4285992816C143998085 @default.
- W4285992816 hasConceptScore W4285992816C2776694085 @default.
- W4285992816 hasConceptScore W4285992816C2777701055 @default.
- W4285992816 hasConceptScore W4285992816C2780057760 @default.
- W4285992816 hasConceptScore W4285992816C2780110267 @default.
- W4285992816 hasConceptScore W4285992816C2992734768 @default.
- W4285992816 hasConceptScore W4285992816C530470458 @default.
- W4285992816 hasConceptScore W4285992816C71924100 @default.
- W4285992816 hasIssue "3" @default.
- W4285992816 hasLocation W42859928161 @default.
- W4285992816 hasLocation W42859928162 @default.
- W4285992816 hasOpenAccess W4285992816 @default.
- W4285992816 hasPrimaryLocation W42859928161 @default.
- W4285992816 hasRelatedWork W1999292713 @default.
- W4285992816 hasRelatedWork W2034849620 @default.
- W4285992816 hasRelatedWork W2534174115 @default.
- W4285992816 hasRelatedWork W2554176272 @default.
- W4285992816 hasRelatedWork W2796582438 @default.
- W4285992816 hasRelatedWork W2948845624 @default.
- W4285992816 hasRelatedWork W3113081998 @default.
- W4285992816 hasRelatedWork W3164806321 @default.
- W4285992816 hasRelatedWork W3186761709 @default.
- W4285992816 hasRelatedWork W4311332848 @default.
- W4285992816 hasVolume "387" @default.
- W4285992816 isParatext "false" @default.
- W4285992816 isRetracted "false" @default.
- W4285992816 workType "article" @default.